Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The conversation is about trying DS Labs SOD supplements for hair loss, which contain ingredients like Genistein, B-sitosterol, and Biotin. The user is considering adding these supplements to their existing hair care routine.

A user humorously discusses hair loss, using treatments like Dutasteride, Finasteride, Minoxidil, and RU58841, and jokingly considers satanic rituals as a solution. The conversation includes satirical responses about trading one's soul for hair.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

Sons are offering free Biotin capsules, Thickening Clay, or Conditioner for hair care testing to UK men. Interested individuals can apply to receive these products without purchase.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

Shiseido's Dermal Sheath Cup (DSC) Hair Multiplication treatment is now available in Japan. Users discuss the treatment's availability and cost.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.

The conversation is a satirical expression of frustration over hair loss, mentioning treatments like spironolactone, microneedling, and topical applications, with references to various hair loss products and personalities in the community.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

Shiseido's S-DSC hair regenerative treatment in Japan focuses on improving existing hair by thickening miniaturized follicles, not creating new ones. There is limited patient feedback and long-term data available.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.

The conversation is about finding a precise scale for measuring melatonin. The user needs to add 5mg per 100ml and finds Amazon scales imprecise.

The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.

A satirical discussion about a 2-year-old cat experiencing hair thinning, humorously suggesting treatments like minoxidil and finasteride. Users joke about the effectiveness and risks of these treatments.

A satirical discussion on intentionally inducing hair loss using harmful habits and substances like cigarettes, junk food, anabolic steroids, and stress. The conversation humorously suggests extreme measures like chemotherapy and hydrofluoric acid, while also mentioning the ineffectiveness of sulfates and pumpkin seed oil in hair loss prevention.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

The conversation is about purchasing Cb-03-01 for research purposes. The user seeks advice on where and how to buy it outside the U.S.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.